Boehringer Ingelheim GmbH-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014346)
◆英語タイトル:Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014346
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:164
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer health care products, animal health care products and biopharmaceuticals. Its products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. The company focuses on the research, development, manufacture and marketing of new drugs of therapeutic value for human and veterinary medicine. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2011 to YTD 2017 14
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Merial Acquires Two Equine Health Products from Bayer HealthCare 22
Merial to Acquire Manufacturing Facility from Merck 23
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 24
Boehringer Ingelheim Plans To Acquire OTC Brands In India 26
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 27
Boehringer Ingelheim Acquires Fremont Facility From Amgen 28
Partnerships 30
Anthem, HealthCore and Boehringer Ingelheim Enter into Agreement 30
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 31
Geisinger Enters into Agreement with Boehringer Ingelheim 32
Boehringer Ingelheim Enters into Partnership with Peking University 33
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 34
Boehringer Ingelheim Enters into Agreement with Weill Cornell Medicine 35
Boehringer Ingelheim Enters into Research Agreement with China Southeast University 36
Boehringer Ingelheim Enters into Agreement with Esteve 37
leadXpro to Enter into Agreement with Boehringer Ingelheim 38
Boehringer Ingelheim Expands Agreement with Sarah Cannon Research Institute 39
Boehringer Ingelheim Enters into Agreement with ViraTherapeutics 40
Boehringer Ingelheim Enters into Research Agreement with Saniona 41
Boehringer Ingelheim and University of Dundee Enter into Agreement 42
Eli Lilly Enters into Agreement with Boehringer Ingelheim 43
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 44
Boehringer Ingelheim Enters into Research Agreement with BioMed X 45
LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 46
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 47
Boehringer May Enter into Agreement with AbbVie 48
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 49
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 50
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 51
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 53
Boehringer Ingelheim and Philogen Enter into Partnership 54
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics 55
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 56
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 57
Boehringer Ingelheim Extends Research Agreement with BioMed X 58
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim 59
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 61
Crystal Biosciences Expands its Agreement with Boehringer Ingelheim to Discover and Develop Therapeutic Antibodies 62
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery 63
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 64
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim 65
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets 66
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture 67
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim 68
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 69
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 70
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 71
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 72
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim 73
Pfenex Enters Into Collaboration With Boehringer Ingelheim 74
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 75
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 76
Licensing Agreements 78
Xynomic Pharma Enters into Licensing Agreement with Boehringer Ingelheim 78
Boehringer Ingelheim Enters into Licensing Agreement with Gubra 79
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 80
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 81
Zealand Pharma Enters into Licensing Agreement with Boehringer 82
Boehringer Ingelheim to Enter into Licensing Agreement with PROvendis 83
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions 84
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 85
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 86
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 87
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 89
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012 90
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 92
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 93
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line 94
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 95
GenVec Enters Into Licensing Agreement With Merial For Vaccine Technology 96
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 97
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 98
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim 99
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim 101
Centegen Enters Into Licensing Agreement With Merial For CEN-102 102
Asset Transactions 103
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 103
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 104
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 105
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 106
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 107
Acquisition 108
Boehringer Ingelheim May Sell Roxane Labs 108
Boehringer Ingelheim GmbH – Key Competitors 109
Boehringer Ingelheim GmbH – Key Employees 110
Boehringer Ingelheim GmbH – Locations And Subsidiaries 111
Head Office 111
Other Locations & Subsidiaries 111
Recent Developments 113
Financial Announcements 113
Aug 02, 2017: Boehringer Ingelheim Achieves Good Growth in the First Half of 2017 113
Apr 05, 2017: Successful financial year 2016 for Boehringer Ingelheim 114
Corporate Communications 115
Jun 10, 2016: Simone Menne – new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance 115
Government and Public Interest 116
Jul 04, 2016: Gaia Novarino wins Boehringer Ingelheim’s FENS Award 2016 for Exceptional Research in Neuroscience 116
Feb 10, 2016: The European Society of Cardiology announces winners of innovative cardiovascular research grant programme 117
Product News 118
12/21/2016: European Medicines Agency: Clinical data for Praxbind now available online 118
12/12/2016: U.S. FDA approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes 119
12/02/2016: FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes 120
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 121
09/08/2016: New analysis showed dose adjustment of Gilotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer 123
08/15/2016: Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind (idarucizumab) Usage in Clinical Practice 124
Jun 21, 2017: New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients 126
06/13/2016: New first-line treatment for lung cancer now funded by Quebec public drug plan (RAMQ) 127
06/11/2016: New Study Results Show Tradjenta (Linagliptin) Reduces Blood Sugar In Adults With Type 2 Diabetes At Risk For Kidney Impairment 128
May 23, 2016: Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing 129
05/15/2017: Pharmaxis Drug Discovery Set To Generate Further €10M Milestone Payment In 2017 As Boehringer Confirms Second Clinical Study 130
04/04/2016: Precision medicine brings new hope to those with advanced urothelial cancer 131
03/08/2016: Praxbind (idarucizumab), Specific Reversal Agent for Pradaxa (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals 133
02/19/2016: New drug reverses the effects of blood thinner in patients with brain hemorrhage 134
02/17/2016: Praxbind(idarucizumab) reimbursed in England, Ireland and Wales 135
01/11/2016: NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies 136
Product Approvals 137
May 16, 2016: Praxbind (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa (dabigatran etexilate) Now Approved in Canada With Conditions 137
Apr 15, 2016: FDA approves Gilotrif (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung 138
Apr 07, 2016: Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung 139
Mar 29, 2016: FDA Approves Supplemental New Drug Application for Boehringer Ingelheim’s STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life 140
Feb 29, 2016: European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung 141
Clinical Trials 142
Aug 24, 2017: Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH 142
Nov 15, 2016: Updated Phase III Results Reinforce Safety and Efficacy of Praxbind (idarucizumab) in Urgent Situations 143
Oct 18, 2016: Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia 144
Sep 05, 2016: New Data: Spiolto Respimat significantly improves exercise capacity in people with COPD 145
Jul 25, 2016: Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials following pre-planned analysis from independent Data Monitoring Committee 146
May 09, 2016: The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer 147
Apr 13, 2016: Head-to-head study demonstrating Gilotrif (afatinib) significantly improved clinical outcomes compared to Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology 149
Apr 02, 2016: Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) in Emergency Situations 151
Feb 09, 2016: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures 153
Jan 27, 2016: Boehringer Ingelheim’s Giotrif / Gilotrif (afatinib) demonstrated superiority to Iressa (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer 155
Jan 25, 2016: Afatinib shows clinical benefit for lung cancer patients with brain metastases 157
Other Significant Developments 158
Nov 20, 2017: Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential 158
Jul 31, 2017: Boehringer Ingelheim And Lilly To Support New American College Of Cardiology Program To Highlight The Increasingly Important Role Of Cardiologists In Reducing Cardiovascular Risk 159
Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim 160
Mar 02, 2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million 161
Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses 162
Jul 20, 2016: The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe 163
Appendix 164
Methodology 164
About GlobalData 164
Contact Us 164
Disclaimer 164

List of Tables
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Boehringer Ingelheim GmbH, Deals By Therapy Area, 2011 to YTD 2017 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2011 to YTD 2017 14
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Merial Acquires Two Equine Health Products from Bayer HealthCare 22
Merial to Acquire Manufacturing Facility from Merck 23
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 24
Boehringer Ingelheim Plans To Acquire OTC Brands In India 26
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 27
Boehringer Ingelheim Acquires Fremont Facility From Amgen 28
Anthem, HealthCore and Boehringer Ingelheim Enter into Agreement 30
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 31
Geisinger Enters into Agreement with Boehringer Ingelheim 32
Boehringer Ingelheim Enters into Partnership with Peking University 33
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 34
Boehringer Ingelheim Enters into Agreement with Weill Cornell Medicine 35
Boehringer Ingelheim Enters into Research Agreement with China Southeast University 36
Boehringer Ingelheim Enters into Agreement with Esteve 37
leadXpro to Enter into Agreement with Boehringer Ingelheim 38
Boehringer Ingelheim Expands Agreement with Sarah Cannon Research Institute 39
Boehringer Ingelheim Enters into Agreement with ViraTherapeutics 40
Boehringer Ingelheim Enters into Research Agreement with Saniona 41
Boehringer Ingelheim and University of Dundee Enter into Agreement 42
Eli Lilly Enters into Agreement with Boehringer Ingelheim 43
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 44
Boehringer Ingelheim Enters into Research Agreement with BioMed X 45
LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 46
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 47
Boehringer May Enter into Agreement with AbbVie 48
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 49
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 50
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 51
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 53
Boehringer Ingelheim and Philogen Enter into Partnership 54
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics 55
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 56
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 57
Boehringer Ingelheim Extends Research Agreement with BioMed X 58
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim 59
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 61
Crystal Biosciences Expands its Agreement with Boehringer Ingelheim to Discover and Develop Therapeutic Antibodies 62
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery 63
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 64
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim 65
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets 66
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture 67
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim 68
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 69
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 70
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 71
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 72
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim 73
Pfenex Enters Into Collaboration With Boehringer Ingelheim 74
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 75
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 76
Xynomic Pharma Enters into Licensing Agreement with Boehringer Ingelheim 78
Boehringer Ingelheim Enters into Licensing Agreement with Gubra 79
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 80
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 81
Zealand Pharma Enters into Licensing Agreement with Boehringer 82
Boehringer Ingelheim to Enter into Licensing Agreement with PROvendis 83
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions 84
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 85
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 86
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 87
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 89
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012 90
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 92
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 93
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line 94
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 95
GenVec Enters Into Licensing Agreement With Merial For Vaccine Technology 96
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 97
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 98
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim 99
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim 101
Centegen Enters Into Licensing Agreement With Merial For CEN-102 102
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 103
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 104
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 105
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 106
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 107
Boehringer Ingelheim May Sell Roxane Labs 108
Boehringer Ingelheim GmbH, Key Competitors 109
Boehringer Ingelheim GmbH, Key Employees 110
Boehringer Ingelheim GmbH, Other Locations 111
Boehringer Ingelheim GmbH, Subsidiaries 111

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Boehringer Ingelheim GmbH-製薬・医療分野:企業M&A・提携分析(Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆